Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Rapid MRSA test firm secures $3.3m; hires new CEO

This article was originally published in Clinica

  • News

Executive Summary

Molecular Detection Inc (MDI), a developer of rapid tests for infectious diseases, has raised $3.3m in series C financing which will be used to launch the company's first product, the Detect-Ready assay for screening methicillin-resistant Staphylococcus aureus (MRSA). The funds were provided by lead investor MentorTech Ventures II and new investors Ben Franklin Technology Partners, Robin Hood Ventures and the Mid-Atlantic Angel Group Fund I and II. Wayne, Pennsylvania-based MDI has also appointed Todd Wallach CEO. Mr Wallach has over 20 years of experience in leading life sciences companies from start-up through global commercialisation.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

ORA’s Chief Says Without Additional Funding, Inspections Are In Jeopardy

News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals

ICER Debuts Clinical Trial Diversity Assessment Framework

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

See All
UsernamePublicRestriction

Register

MT044545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By